J0132Acetylcysteine injection
Published CMS Medicare Part B payment-limit context for J0132, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$0.389
per 100 MG · Medicare Part B
Down 23.9%from $0.511 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$0.5973$0.3387
2024-Q4: $0.569; 2025-Q1: $0.545; 2025-Q2: $0.446; 2025-Q3: $0.369; 2025-Q4: $0.385; 2026-Q1: $0.367; 2026-Q2: $0.511; 2026-Q3: $0.389
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Acetylcysteine ingredient family (FDA data as of August 20, 2026).
Acetylcysteine
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Acetylcysteine presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J7608 | Acetylcysteine non-comp unit | $7.274 per 1 GM | $8.541 per 1 GM | Down 14.8% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.